Addus HomeCare (ADUS)
(Real Time Quote from BATS)
$119.04 USD
+0.22 (0.19%)
Updated Jul 22, 2024 11:06 AM ET
3-Hold of 5 3
B Value A Growth B Momentum A VGM
Addus HomeCare (ADUS) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$124.89 | $136.00 | $83.00 | 5.11% |
Price Target
Based on short-term price targets offered by nine analysts, the average price target for Addus HomeCare comes to $124.89. The forecasts range from a low of $83.00 to a high of $136.00. The average price target represents an increase of 5.11% from the last closing price of $118.82.
Analyst Price Targets (9 )
Broker Rating
Addus HomeCare currently has an average brokerage recommendation (ABR) of 1.60 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 10 brokerage firms. The current ABR compares to an ABR of 1.67 a month ago based on nine recommendations.
Of the 10 recommendations deriving the current ABR, seven are Strong Buy and two are Buy. Strong Buy and Buy respectively account for 70% and 20% of all recommendations. A month ago, Strong Buy made up 66.67%, while Buy represented 22.22%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/ADUS.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 7 | 7 | 6 | 6 | 6 |
Buy | 2 | 2 | 2 | 2 | 2 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 1 | 1 | 1 | 1 | 1 |
ABR | 1.60 | 1.60 | 1.67 | 1.67 | 1.67 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
6/28/2024 | Macquarie Capital Securities | Tao Qiu | Not Available | Strong Buy |
5/7/2024 | Stephens | Scott Fidel | Strong Buy | Strong Buy |
5/6/2024 | William Blair | Jared Haase | Strong Buy | Strong Buy |
4/23/2024 | Not Identified | Not Identified | Hold | Strong Sell |
4/1/2024 | Cowen & Co. | Ryan Langston | Strong Buy | Strong Buy |
3/26/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
2/29/2024 | Not Identified | Not Identified | Moderate Buy | Moderate Buy |
2/27/2024 | Raymond James | John W Ransom | Moderate Buy | Moderate Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.60 |
ABR (Last week) | 1.60 |
# of Recs in ABR | 10 |
Average Target Price | $124.89 |
LT Growth Rate | 11.90% |
Industry | Medical - Outpatient and Home Healthcare |
Industry Rank by ABR | 63 of 252 |
Current Quarter EPS Est: | 1.20 |